Lilly has voiced strong support for the US administration’s goal of keeping the country the world’s leading destination for biopharmaceutical research and manufacturing — while urging other developed markets to take on a greater share of drug costs.

In a statement released earlier this month, the company said the rebalancing of costs across countries “may be difficult,” but that prices for medicines paid by governments and health systems in markets like Europe need to increase in order to make them lower in the US.

According to Lilly, medicine prices should reflect their value for patients, health systems, and society. The company said it has intensified efforts to align prices across developed countries, especially in Europe, and expects to make adjustments by September 1. This includes an agreement with the UK government to increase the list price of Mounjaro while maintaining access for NHS patients.

In the US, Lilly pointed to steps it has already taken to lower patient costs — scaling Lilly Direct to provide more affordable access to medicines including Zepbound, reducing insulin prices by 70%, and capping monthly out-of-pocket costs at $35.

The company also highlighted structural issues in the US system — including cross subsidies, abuse of government programs like 340B, and patient insurance cost-sharing — that it says have driven higher drug prices compared to other developed nations.

Since 2020, Lilly said it has committed over $50 billion to US manufacturing expansion, with 10 active projects designed to supply the domestic market and increase exports. An additional $5 billion has been earmarked for capacity expansion overseas.

The company also voiced opposition to tariffs on pharmaceutical products. Medicines have traditionally been excluded from tariffs because of their life-saving nature, Lilly noted, warning that broad tariffs could raise costs, limit access, and undermine American leadership.

“Lilly remains committed to working with the administration on drug-pricing reforms that benefit patients and sustain America’s leadership in biomedical innovation,” the statement concluded.